Drugs / Janssen Ad26.CoV2.S Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05220397 | Apr 2022 → Feb 2025 | — | Mark Stegall | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Janssen Ad26.CoV2.S Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05220397 ↗ |
| Known as | Janssen Ad26.COV2.S | “OBJECTIVE: To assess heterologous booster (HB) with Janssen Ad26.COV2.S in kidney transplant recipients (KTRs) with low antibody levels after multiple COVID-19 mRNA vaccinations.” PMID 40663029 ↗ Jul 2025 |
| Modality | Vaccine | “Janssen Ad26.COV2.S vaccine” NCT05220397 ↗ |